Combined assessment of serum alpha-synuclein and RAB35 is a better biomarker for Parkinson’s disease

Hung Li Wang; Chin Song Lu; Tu Hsueh Yeh; Yu Ming Shen; Yi Hsin Weng; Ying Zu Huang; Rou Shayn Chen; Yu Chuan Liu; Yi Chuan Cheng; Hsiu Chen Chang; Ying Ling Chen; Yu Jie Chen; Yan Wei Lin; Chia Chen Hsu; Huang Li Lin; Chi Han Chiu; Ching Chi Chiu

doi:10.3988/jcn.2019.15.4.488

Combined assessment of serum alpha-synuclein and RAB35 is a better biomarker for Parkinson’s disease

Hung Li Wang, Chin Song Lu, Tu Hsueh Yeh, Yu Ming Shen, Yi Hsin Weng, Ying Zu Huang, Rou Shayn Chen, Yu Chuan Liu, Yi Chuan Cheng, Hsiu Chen Chang, Ying Ling Chen, Yu Jie Chen, Yan Wei Lin, Chia Chen Hsu, Huang Li Lin, Chi Han Chiu, Ching Chi Chiu

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Background and Purpose It is essential to develop a reliable predictive serum biomarker for Parkinson’s disease (PD). The accumulation of alpha-synuclein (αSyn) and up-regulated expression of Rab35 participate in the etiology of PD. The purpose of this investigation was to determine whether the combined assessment of serum αSyn and Rab35 is a useful predictive biomarker for PD. Methods Serum levels of αSyn or Rab35 were determined in serum samples from 59 sporadic PD patients, 19 progressive supranuclear palsy (PSP) patients, 20 multiple system atrophy (MSA) patients, and 60 normal controls (NC). Receiver operating characteristics (ROC) curves were calculated to determine the diagnostic accuracy of αSyn or/and Rab35 in discriminating PD patients from NC or atypical parkinsonian patients. Results The levels of αSyn and Rab35 were increased in PD patients. The serum level of Rab35 was positively correlated with that of αSyn in PD patients. Compared to analyzing αSyn or Rab35 alone, the combined analysis of αSyn and Rab35 produced a larger area under the ROC curve and performed better in discriminating PD patients from NC, MSA patients, or PSP patients. When age was dichotomized at 55, 60, 65, or 70 years, the combined assessment of αSyn and Rab35 for classifying PD was better in the group below the cutoff age than in the group above the cutoff age. Conclusions Combined assessment of serum αSyn and Rab35 is a better biomarker for discriminating PD patients from NC or atypical parkinsonian patients, and is a useful predictive biomarker for younger sporadic PD patients.

Original language	English
Pages (from-to)	488-495
Number of pages	8
Journal	Journal of Clinical Neurology (Korea)
Volume	15
Issue number	4
DOIs	https://doi.org/10.3988/jcn.2019.15.4.488
Publication status	Published - Oct 2019

Keywords

Alpha-synuclein
Biomarker
Rab35
Serum
‌Parkinson’s disease

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.3988/jcn.2019.15.4.488

Cite this

Wang, H. L., Lu, C. S., Yeh, T. H., Shen, Y. M., Weng, Y. H., Huang, Y. Z., Chen, R. S., Liu, Y. C., Cheng, Y. C., Chang, H. C., Chen, Y. L., Chen, Y. J., Lin, Y. W., Hsu, C. C., Lin, H. L., Chiu, C. H., & Chiu, C. C. (2019). Combined assessment of serum alpha-synuclein and RAB35 is a better biomarker for Parkinson’s disease. Journal of Clinical Neurology (Korea), 15(4), 488-495. https://doi.org/10.3988/jcn.2019.15.4.488

Wang, HL, Lu, CS, Yeh, TH, Shen, YM, Weng, YH, Huang, YZ, Chen, RS, Liu, YC, Cheng, YC, Chang, HC, Chen, YL, Chen, YJ, Lin, YW, Hsu, CC, Lin, HL, Chiu, CH & Chiu, CC 2019, 'Combined assessment of serum alpha-synuclein and RAB35 is a better biomarker for Parkinson’s disease', Journal of Clinical Neurology (Korea), vol. 15, no. 4, pp. 488-495. https://doi.org/10.3988/jcn.2019.15.4.488

@article{6a94fd2db3ca4a338d2fe164f7d33434,

title = "Combined assessment of serum alpha-synuclein and RAB35 is a better biomarker for Parkinson{\textquoteright}s disease",

abstract = "Background and Purpose It is essential to develop a reliable predictive serum biomarker for Parkinson{\textquoteright}s disease (PD). The accumulation of alpha-synuclein (αSyn) and up-regulated expression of Rab35 participate in the etiology of PD. The purpose of this investigation was to determine whether the combined assessment of serum αSyn and Rab35 is a useful predictive biomarker for PD. Methods Serum levels of αSyn or Rab35 were determined in serum samples from 59 sporadic PD patients, 19 progressive supranuclear palsy (PSP) patients, 20 multiple system atrophy (MSA) patients, and 60 normal controls (NC). Receiver operating characteristics (ROC) curves were calculated to determine the diagnostic accuracy of αSyn or/and Rab35 in discriminating PD patients from NC or atypical parkinsonian patients. Results The levels of αSyn and Rab35 were increased in PD patients. The serum level of Rab35 was positively correlated with that of αSyn in PD patients. Compared to analyzing αSyn or Rab35 alone, the combined analysis of αSyn and Rab35 produced a larger area under the ROC curve and performed better in discriminating PD patients from NC, MSA patients, or PSP patients. When age was dichotomized at 55, 60, 65, or 70 years, the combined assessment of αSyn and Rab35 for classifying PD was better in the group below the cutoff age than in the group above the cutoff age. Conclusions Combined assessment of serum αSyn and Rab35 is a better biomarker for discriminating PD patients from NC or atypical parkinsonian patients, and is a useful predictive biomarker for younger sporadic PD patients.",

keywords = "Alpha-synuclein, Biomarker, Rab35, Serum, ‌Parkinson{\textquoteright}s disease",

author = "Wang, {Hung Li} and Lu, {Chin Song} and Yeh, {Tu Hsueh} and Shen, {Yu Ming} and Weng, {Yi Hsin} and Huang, {Ying Zu} and Chen, {Rou Shayn} and Liu, {Yu Chuan} and Cheng, {Yi Chuan} and Chang, {Hsiu Chen} and Chen, {Ying Ling} and Chen, {Yu Jie} and Lin, {Yan Wei} and Hsu, {Chia Chen} and Lin, {Huang Li} and Chiu, {Chi Han} and Chiu, {Ching Chi}",

note = "Funding Information: This work was supported by the Ministry of Science and Technology, Taiwan (grant MOST107-2320-B-182-036-MY3 to H.L.W. and grant MOST106-2314-B-182A-012-MY3 to C.C.C.) and the Chang Gung Medical Foundation (grants CMRPD1C0623, CRRPD1C0013, CMRPD180433, CMRPD1B0332, EMRPD1G0171, and CMRPD1H0281 to H.L.W., and grants CMRPG3F1823 and CMRPG3J0761 to C.C.C.). Funding Information: This work was supported by the Ministry of Science and Technology, Taiwan (grant MOST 107-2320-B-182-036-MY3 to H.L.W. and grant MOST 106-2314-B-182A-012-MY3 to C.C.C.) and the Chang Gung Medical Foundation (grants CMRPD1C0623, CRRPD1C0013, CMRPD180433, CMRPD1B0332, EMRPD1G0171, and CMRPD1H0281 to H.L.W., and grants CMRPG3F1823 and CMRPG3J0761 to C.C.C.). Publisher Copyright: {\textcopyright} 2019 Korean Neurological Association.",

year = "2019",

month = oct,

doi = "10.3988/jcn.2019.15.4.488",

language = "English",

volume = "15",

pages = "488--495",

journal = "Journal of Clinical Neurology (Korea)",

issn = "1738-6586",

publisher = "Korean Neurological Association",

number = "4",

}

TY - JOUR

T1 - Combined assessment of serum alpha-synuclein and RAB35 is a better biomarker for Parkinson’s disease

AU - Wang, Hung Li

AU - Lu, Chin Song

AU - Yeh, Tu Hsueh

AU - Shen, Yu Ming

AU - Weng, Yi Hsin

AU - Huang, Ying Zu

AU - Chen, Rou Shayn

AU - Liu, Yu Chuan

AU - Cheng, Yi Chuan

AU - Chang, Hsiu Chen

AU - Chen, Ying Ling

AU - Chen, Yu Jie

AU - Lin, Yan Wei

AU - Hsu, Chia Chen

AU - Lin, Huang Li

AU - Chiu, Chi Han

AU - Chiu, Ching Chi

N1 - Funding Information: This work was supported by the Ministry of Science and Technology, Taiwan (grant MOST107-2320-B-182-036-MY3 to H.L.W. and grant MOST106-2314-B-182A-012-MY3 to C.C.C.) and the Chang Gung Medical Foundation (grants CMRPD1C0623, CRRPD1C0013, CMRPD180433, CMRPD1B0332, EMRPD1G0171, and CMRPD1H0281 to H.L.W., and grants CMRPG3F1823 and CMRPG3J0761 to C.C.C.). Funding Information: This work was supported by the Ministry of Science and Technology, Taiwan (grant MOST 107-2320-B-182-036-MY3 to H.L.W. and grant MOST 106-2314-B-182A-012-MY3 to C.C.C.) and the Chang Gung Medical Foundation (grants CMRPD1C0623, CRRPD1C0013, CMRPD180433, CMRPD1B0332, EMRPD1G0171, and CMRPD1H0281 to H.L.W., and grants CMRPG3F1823 and CMRPG3J0761 to C.C.C.). Publisher Copyright: © 2019 Korean Neurological Association.

PY - 2019/10

Y1 - 2019/10

N2 - Background and Purpose It is essential to develop a reliable predictive serum biomarker for Parkinson’s disease (PD). The accumulation of alpha-synuclein (αSyn) and up-regulated expression of Rab35 participate in the etiology of PD. The purpose of this investigation was to determine whether the combined assessment of serum αSyn and Rab35 is a useful predictive biomarker for PD. Methods Serum levels of αSyn or Rab35 were determined in serum samples from 59 sporadic PD patients, 19 progressive supranuclear palsy (PSP) patients, 20 multiple system atrophy (MSA) patients, and 60 normal controls (NC). Receiver operating characteristics (ROC) curves were calculated to determine the diagnostic accuracy of αSyn or/and Rab35 in discriminating PD patients from NC or atypical parkinsonian patients. Results The levels of αSyn and Rab35 were increased in PD patients. The serum level of Rab35 was positively correlated with that of αSyn in PD patients. Compared to analyzing αSyn or Rab35 alone, the combined analysis of αSyn and Rab35 produced a larger area under the ROC curve and performed better in discriminating PD patients from NC, MSA patients, or PSP patients. When age was dichotomized at 55, 60, 65, or 70 years, the combined assessment of αSyn and Rab35 for classifying PD was better in the group below the cutoff age than in the group above the cutoff age. Conclusions Combined assessment of serum αSyn and Rab35 is a better biomarker for discriminating PD patients from NC or atypical parkinsonian patients, and is a useful predictive biomarker for younger sporadic PD patients.

AB - Background and Purpose It is essential to develop a reliable predictive serum biomarker for Parkinson’s disease (PD). The accumulation of alpha-synuclein (αSyn) and up-regulated expression of Rab35 participate in the etiology of PD. The purpose of this investigation was to determine whether the combined assessment of serum αSyn and Rab35 is a useful predictive biomarker for PD. Methods Serum levels of αSyn or Rab35 were determined in serum samples from 59 sporadic PD patients, 19 progressive supranuclear palsy (PSP) patients, 20 multiple system atrophy (MSA) patients, and 60 normal controls (NC). Receiver operating characteristics (ROC) curves were calculated to determine the diagnostic accuracy of αSyn or/and Rab35 in discriminating PD patients from NC or atypical parkinsonian patients. Results The levels of αSyn and Rab35 were increased in PD patients. The serum level of Rab35 was positively correlated with that of αSyn in PD patients. Compared to analyzing αSyn or Rab35 alone, the combined analysis of αSyn and Rab35 produced a larger area under the ROC curve and performed better in discriminating PD patients from NC, MSA patients, or PSP patients. When age was dichotomized at 55, 60, 65, or 70 years, the combined assessment of αSyn and Rab35 for classifying PD was better in the group below the cutoff age than in the group above the cutoff age. Conclusions Combined assessment of serum αSyn and Rab35 is a better biomarker for discriminating PD patients from NC or atypical parkinsonian patients, and is a useful predictive biomarker for younger sporadic PD patients.

KW - Alpha-synuclein

KW - Biomarker

KW - Rab35

KW - Serum

KW - ‌Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=85073553333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073553333&partnerID=8YFLogxK

U2 - 10.3988/jcn.2019.15.4.488

DO - 10.3988/jcn.2019.15.4.488

M3 - Article

AN - SCOPUS:85073553333

SN - 1738-6586

VL - 15

SP - 488

EP - 495

JO - Journal of Clinical Neurology (Korea)

JF - Journal of Clinical Neurology (Korea)

IS - 4

ER -

Combined assessment of serum alpha-synuclein and RAB35 is a better biomarker for Parkinson’s disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this